PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: Evaluation of the additive value after conventional imaging

American Journal of Roentgenology

Volumn 198, Issue 4, 2012, Pages 902-908

  Bronstein, Yulia ^a   Ng, Chaan S ^b   Rohren, Eric ^b   Ross, Merrick I ^b   Lee, Jeffrey E ^b   Cormier, Janice ^b   Johnson, Valen E ^b   Hwu, Wen Jen ^b  

^a Virtual Radiologic   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Additive value; FDG PET; Imaging; Melanoma; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADRENAL METASTASIS; ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FALSE POSITIVE RESULT; FEMALE; HUMAN; IN-TRANSIT METASTASIS; LIMB METASTASIS; LIMB PERFUSION; LYMPH NODE METASTASIS; MALE; MELANOMA; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREOPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOFT TISSUE METASTASIS; TREATMENT PLANNING; TUMOR BIOPSY; VISCERAL METASTASIS;

ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84859127511     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.11.7280     Document Type: Article

References (15)

1. Coit DG, Andtbacka R, Anker CJ, et al. Melanoma: NCCN guidelines for patients. Fort Washington, PA: National Comprehensive Cancer Network, NCCN clinical practice guidelines in oncology. 2011:1-80
2. Choi EA, Gershenwald JE. Imaging studies in patients with melanoma. Surg Oncol Clin N Am 2007; 16:403-430
3. Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a metaanalysis. J Natl Cancer Inst 2011; 103:129-142
4. Tyler DS, Onaitis M, Kherani A, et al. Positron emission tomography scanning in malignant melanoma. Cancer 2000; 89:1019-1025
5. Miranda EP, Gertner M, Wall J, et al. Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. Arch Surg 2004; 139:831-836, discussion 836-837
6. Buzaid AC, Sandler AB, Mani S, et al. Role of computed tomography in the staging of primary melanoma. J Clin Oncol 1993; 11:638-643
7. Strobel K, Dummer R, Husarik DB, Pérez Lago M, Hany TF, Steinert HC. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology 2007; 244:566-574
8. Mohr P, Eggermont AM, Hauschild A, Buzaid A. Staging of cutaneous melanoma. Ann Oncol 2009; 20(suppl 6):vi14-vi21
9. 18F-fluorodeoxyglucose positron emission tomography in recurrent melanoma. Nucl Med Commun 2002; 23:475-481
10. Gulec SA, Faries MB, Lee CC, et al. The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making. Clin Nucl Med 2003; 28:961-965
11. Brady MS, Akhurst T, Spanknebel K, et al. Utility of preoperative [(18)]f fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients. Ann Surg Oncol 2006; 13:525-532
12. Harris MT, Berlangieri SU, Cebon JS, Davis ID, Scott AM. Impact of 2-deoxy-2[F-18]fluoro-Dglucose positron emission tomography on the management of patients with advanced melanoma. Mol Imaging Biol 2005; 7:304-308
13. 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 2006; 24:1178-1187
14. 18F-FDG PET/CT imaging for patients with malignant melanoma. Nucl Med Commun 2007; 28:688-695
15. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer 2007; 43:557-564